-
Product Insights
Complement C3 – Drugs In Development, 2023
Global Markets Direct’s Complement C3 provides in depth analysis on Complement C3 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Complement C3 targeted therapeutics development and features...
-
Product Insights
Cajuina C3
Cajuina C3 is an Onshore Wind project located in Rio Grande do Norte, Brazil. The project is owned by AES Brasil Energia SA and is developed by JMalucelli Energia S.A; Serra Verde V Energetica SA. The project is at the permitting stage. Empower your strategies with our Cajuina C3 report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of...
-
Product Insights
Fora C3 Lytyachi Solar PV Park
Fora C3 Lytyachi Solar PV Park is a solar PV project located in Ternopil, Ukraine. The project came online in 2019. Empower your strategies with our Fora C3 Lytyachi Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegcetacoplan in Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegcetacoplan in Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegcetacoplan in Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis) Drug Details: Pegcetacoplan (Empaveli,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegcetacoplan in Membranous Glomerulonephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegcetacoplan in Membranous Glomerulonephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegcetacoplan in Membranous Glomerulonephritis Drug Details: Pegcetacoplan (Empaveli, Aspaveli) is a synthetic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegcetacoplan in IgA Nephropathy (Berger’s Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegcetacoplan in IgA Nephropathy (Berger's Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegcetacoplan in IgA Nephropathy (Berger's Disease) Drug Details: Pegcetacoplan (Empaveli,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegcetacoplan in Glomerulonephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegcetacoplan in Glomerulonephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegcetacoplan in Glomerulonephritis Drug Details: Pegcetacoplan (Empaveli, Aspaveli) is a synthetic peptide acts...
-
Company Insights
Innovation and Patenting activity of C3.ai Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of C3.ai Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HRS-5965 in Lupus Nephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HRS-5965 in Lupus Nephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HRS-5965 in Lupus Nephritis Drug Details: HRS-5965 is under development for the...